General MedicationsOPHTHALMICGeneric

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

Standard Dose

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

Max Dose

Refer to approved labeling

Primary Use

Review priority: UNKNOWN Marketing status: Discontinued

Summary

Approval overview NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE is listed in Drugs@FDA under application 065213 (ANDA).

Review priority: UNKNOWN Marketing status: Discontinued Active ingredient BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE Form and strength OINTMENT;OPHTHALMIC - 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM Sponsor SCIEGEN PHARMS Submission history Latest submission status date: 2017-03-10 00:00:00.

Structured Monograph

Clinical summary

Approval overview NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE is listed in Drugs@FDA under application 065213 (ANDA). Review priority: UNKNOWN Marketing status: Discontinued Active ingredient BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE Form and strength OINTMENT;OPHTHALMIC - 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM Sponsor SCIEGEN PHARMS Submission history Latest submission status date: 2017-03-10 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: UNKNOWN

Interaction Notes

No interaction notes stored yet.